A cooperative process to reach mutually acceptable solutions that respects all stakeholders, improves our common understanding and establishes sustainable mutual trust.

The 2nd Multi-Stakeholder Symposium was made possible thanks to the support of Members of the EURORDIS Round Table of Companies. We would particularly like to thank the following companies for their exceptional support:

- Alnylam
- BioMarin
- Celgene
- CSL Behring
- Novartis
- Pfizer
- QuintilesIMS
- Roche
- Sanofi Genzyme
- Shire

A EURODIA RARE DISEASE DAY EVENT

IN PARTNERSHIP WITH

IN PARTNERSHIP WITH

#RareEU2017
#RareEU2017
DAY 1
WEDNESDAY 22 FEBRUARY 2017
9.00 to 13.00

Session: Panel Discussion: the importance of multi-stakeholder collaboration in rare diseases
Moderator: Juri-Georg Eriksen, Senior Medical Officer, DR
Panellists:
- Marie-Dominique Guigou, Head of Healthcare Policy, Pharmaceutical Research & Manufacturers of America (PhRMA)
- Charles Barker, Director General, EURORDIS
- Charles Volkmann, Group Leader, Data Generation, Innovation Centre, Pfizer

13.00 – 14.00 Lunch (Adolphe Max room)

14.00 – 15.45 Multi-stakeholder panel debates successes for collaboration in rare diseases
G&M Forum on-air and online audience

Moderator: Marie-Georg Eriksen, Senior Medical Officer, DR
Panellists:
- Sari Stokroos, Project Manager, EURACTIV Website, and Project Lead, Crisis Group, Adam Sackman, Project Manager, Health and World Bank Group, Laura Berthoud, Director General, ADRES-BIO
- Sanne van Haren, President of European Federation of Orphan Societies, Austria
- Beth Symanski, Deputy Administrator of the President’s International AIDS Hazards, and Aid Initiatives, Global Fund to Fight AIDS, Tuberculosis and Malaria, Simon Day, Director, Clinical Trials Consulting & Training Limited, UK

DAY 2
THURSDAY 23 FEBRUARY 2017
9.00 to 10.00

10.00 – 11.15 Panel Discussion: success factors for collaboration in relation to access
Theatre room

Moderator: Christiane Meurice, Chief Executive Officer, EURORDIS, Germany
Panellists:
- Nathalie Van Lancker, Head of Rare Diseases – Roboleo & Co, UK
- Charlotte Novartis, Switzerland; Director Healthcare Systems, Verteil, Ruediger Hach, Lieven Annemans, Director, Dolon Ltd., UK;
- Sheela Upadhyaya, UK; Vice President, CRA International

11.15 – 12.30 Discussion from afternooon breakout sessions – year of innovations
Theatre room

Moderator: Karen Facey, Director General, EURORDIS, Germany
Panelists:
- Marco Roos, Group leader Medical Genetics, Dr Horst Schmidt Clinic, Germany;
- Vinciane Debroux-Pirard, Research Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK
- Gottfried Endel, Affaires Director, EURORDIS, France
- Alexander Natz, RD-ACTION Thematic Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK

12.30 – 13.00 Lunch (Adolphe Max room)

15.15 – 15.30 PLENARY Theatre room

Chair: Sandra Nestler-Parr, Co-Chair GPCR RARE Disease Special Interest Group, Trustee – Alpha UK Support Group, Chair of Rare Diseases – Roboleo & Co, UK; and Charles Barker, Director General, EURORDIS

15.30 – 16.00 Breakout sessions  – new options

Breakout 1: Outcomes
Rapporteur: Ingrid Schulz-Delkorn, European Public Affairs, Novo Nordisk

Moderators:
- Marco Roos, Group leader Medical Genetics, Dr Horst Schmidt Clinic, Germany;
- Vinciane Debroux-Pirard, Research Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK
- Gottfried Endel, Affaires Director, EURORDIS, France
- Alexander Natz, RD-ACTION Thematic Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK

Rapporteurs from breakouts
- Charlie Haux, National Health Committee of Austria
- Alexander Natz, RD-ACTION Thematic Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK

16.00 – 17.00 Feedback and discussion from afternoon breakout sessions
Rapporteur: Karen Facey, Director General, EURORDIS, Germany
Moderators:
- Marco Roos, Group leader Medical Genetics, Dr Horst Schmidt Clinic, Germany;
- Vinciane Debroux-Pirard, Research Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK
- Gottfried Endel, Affaires Director, EURORDIS, France
- Alexander Natz, RD-ACTION Thematic Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK

17.00 – 18.30 PLENARY Theatre room

Chair: Sandra Nestler-Parr, Co-Chair GPCR RARE Disease Special Interest Group, Trustee – Alpha UK Support Group, Head of Rare Diseases – Roboleo & Co, UK; and Charles Barker, Director General, EURORDIS

17.30 – 17.50 Breakout sessions  – new options

Breakout 6: Outcomes
Rapporteur: Ingrid Schulz-Delkorn, European Public Affairs, Novo Nordisk

Moderators:
- Marco Roos, Group leader Medical Genetics, Dr Horst Schmidt Clinic, Germany;
- Vinciane Debroux-Pirard, Research Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK
- Gottfried Endel, Affaires Director, EURORDIS, France
- Alexander Natz, RD-ACTION Thematic Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK

Rapporteurs from breakouts
- Charlie Haux, National Health Committee of Austria
- Alexander Natz, RD-ACTION Thematic Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK

18.00 – 19.30 Feedback and discussion from afternoon breakout sessions
Rapporteur: Karen Facey, Director General, EURORDIS, Germany
Moderators:
- Marco Roos, Group leader Medical Genetics, Dr Horst Schmidt Clinic, Germany;
- Vinciane Debroux-Pirard, Research Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK
- Gottfried Endel, Affaires Director, EURORDIS, France
- Alexander Natz, RD-ACTION Thematic Coordinator for Rare Diseases at Newcastle University Institute of Genetic Medicine, UK

19.00 – 20.00 Conclusions & closing remarks

Moderator: Karen Facey, Chief Executive Officer, EURORDIS, Germany